Navigation Links
Campbell Alliance Brand Management Practice to Present at EyeForPharma's Oncology Summit USA and Oncology Market Access Europe Conference
Date:3/10/2009

RALEIGH, N.C., March 10 /PRNewswire/ -- Campbell Alliance, the leading management consulting firm specializing in the pharmaceutical and biotech industry, today announced that Ashwin Dandekar, Vice President, Brand Management Practice, will present a session at EyeforPharma's Oncology Summit USA on March 30 and 31, 2009 at the Boston Park Plaza Hotel in Boston, Massachusetts. Dr. Dandekar will also present a workshop at EyeForPharma's Oncology Market Access Europe Conference, scheduled for April 22 and 23, 2009 at the Zurich Marriott Hotel in Zurich, Switzerland.

Dr. Dandekar's presentation at EyeforPharma's Oncology Summit USA is scheduled for 3:30 pm March 30 as a part of "Session 3: Market Access and Early Commercialization". His presentation, titled "The Building Blocks of Successful Oncology Commercialization," will examine the four building blocks for maximizing the commercial value of new oncology products. Specifically, the presentation will focus on developing long-term vision for products in tandem with comprehensive market-entry strategies, creating winning labels and development programs, assessing and developing markets, and building the company's infrastructure and resources to put into action commercialization strategies.

At EyeforPharma's Oncology Market Access Europe Conference, Dr. Dandekar will present a workshop at 2:00 pm on April 20. His workshop, also titled "The Building Blocks of Successful Oncology Commercialization," will similarly examine the essential elements of maximizing commercial value for oncology products, but will focus on commercialization in European markets.

"The oncology market is undoubtedly complicated as products themselves are complex, market competition is fierce, and there are many strategic and organizational challenges that result from the specialized nature of the products," Dr. Dandekar said. "Consequently, oncology product commercialization can be highly complex."

Dr. Dandekar leverages his training as a physician and his consulting experience to help clients across the pharmaceutical, biotech, and healthcare industries. He has particular expertise in combining clinical knowledge with sound marketing skills to assist clients with new product strategy, market analysis, and product positioning. Prior to consulting, Dr. Dandekar worked as a research analyst at the University Hospitals of Cleveland, and as a physician and administrative director at Dandekar Hospital in Bombay, India. Dr. Dandekar received his MBA from the Weatherhead School of Management at Case Western Reserve University and an MBBS from MGM Medical School and Hospital, Bombay University.

For more information on EyeforPharma's Oncology Summit USA, please visit

http://www.eyeforpharma.com/oncologyusa09.

For more information on EyeforPharma's Oncology Market Access Europe Conference, please visit

http://www.eyeforpharma.com/oncology09.

Executives from Campbell Alliance speak at many conferences in the US and Europe each year. For a full listing of events, please refer to the company's online conference calendar at http://www.campbellalliance.com/pressroom/eventcalendar.cfm.

About the Brand Management Practice at Campbell Alliance

The Brand Management Practice at Campbell Alliance can help enhance the commercial performance of products from initial launch through product maturity. The firm's team members are experts at new product planning, commercial strategy development, brand planning, product launch, and myriad other aspects of maximizing the value of pharmaceutical assets. The team has also developed commercial strategies and programs in various geographic markets, including the US, Canada, Europe, and Latin America. Services include

  • Portfolio planning
  • New product planning
  • Launch excellence
  • Growth maximization
  • Life cycle extension
  • Capability enhancement

About Campbell Alliance

Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industry. The firm's clients include most of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Business Development, Clinical Development, Managed Markets, Sales, and Trade and Distribution. From its locations in Raleigh, NC, Parsippany, NJ, Los Angeles, San Francisco, Chicago, Boston, Philadelphia, New York City, Atlanta, and London, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit http://www.campbellalliance.com.

                          CONTACT:
                          James Forte
                          Director, Public and Media Relations
                          Campbell Alliance
                          919-844-7100, extension 7195
                          jforte@campbellalliance.com


'/>"/>
SOURCE Campbell Alliance
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Campbell Alliance Hires Joe Dillon, Expands Business Development Practice
2. Campbell Alliance Sales Practice to Present at CBIs Leadership Summit on Evolving the Pharma Sales Model
3. Nader Naeymi-Rad Appointed Chief Operating Officer at Campbell Alliance
4. Darius Naigamwalla Appointed Senior Vice President and Head of the Brand Management Practice at Campbell Alliance
5. Pharmaceutical Institute, in Collaboration With Campbell Alliance, Releases Second Edition of Breakthrough Book on the Inner Workings of the Pharmaceutical Industry
6. Campbell Alliance Clinical Development Practice to Conduct Two Workshops at 44th DIA Annual Meeting
7. Campbell Alliance Trade and Distribution Practice to Speak at CBIs Commercial Contracts and Chargeback Management Conference
8. Campbell Alliance Sales Practice to Present Workshop at SPBT Annual Conference
9. Campbell Alliance Clinical Development Practice to Present Session on Global EDC Rollout at Clinical Trials Congress, Europe
10. Campbell Alliance Adds Doug Linton, Former Cardinal Health Executive, to Executive Advisory Group
11. Campbell Alliance Managed Markets Practice to Take a Leadership Role at the CBI Forum on Effective Product Pricing and Modeling Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks ... to industrial engineering, was today awarded as one ... selection of the world,s most innovative companies. Ginkgo ... scale for the real world in the nutrition, ... engineers work directly with customers including Fortune 500 ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/24/2016)... ... 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona ... or pleural mesothelioma. Their findings are the subject of a new article on the ... are signposts in the blood, lung fluid or tissue of mesothelioma patients that can ...
(Date:6/23/2016)... ... 2016 , ... UAS LifeSciences, one of the leading manufacturers ... Probiotics, into Target stores nationwide. The company, which has been manufacturing high quality ... list of well-respected retailers. This list includes such fine stores as Whole Foods, ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
Breaking Biology News(10 mins):